What is Cytomegalovirus and how does it affect you? Learn more about a clinical trial now enrolling
BRIDGEPORT, Conn. (PRWEB) July 27, 2023 -- New Clinical Trial to Enroll for Cytomegalovirus (CMV) Investigational Vaccine, Evaluating Efficacy and Safety in Women 16 to 40 Years of Age.
New England Research Associates, a leading clinical research facility in the Tri-State area, is excited to announce its participation in a clinical trial focused on evaluating the safety and effectiveness of an investigational cytomegalovirus (CMV) vaccine developed by Moderna, a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines. This trial aims to see whether the investigational vaccine can safeguard the health of unborn babies, specifically targeting women between the ages of 16 and 40 who are actively involved in childcare or in frequent contact with children if 20 – 40 years of age.
CMV, a prevalent virus affecting women of all ages, poses significant risks to pregnant women and their unborn babies. Congenital CMV, an infection that can be passed from mother to fetus during pregnancy, can result in severe complications, including hearing loss, vision problems, developmental delays, and other long-term disabilities. The trial will enroll a diverse group of women who will receive the investigational CMV vaccine, and their overall health will be closely monitored throughout the trial.
Dr. Ilja Hulinsky, Principal Investigator of New England Research Associates, expressed enthusiasm about the trial, stating, "We are excited to embark on this journey, working alongside passionate researchers and volunteers, to potentially make a meaningful difference in the lives of women, babies, and families affected by CMV. Together, we will join forces to combat CMV and potentially pave the way for a healthier and brighter future.”
The research team hopes this trial will provide valuable insights into developing an effective vaccine to prevent CMV infection. By monitoring patient outcomes and responses, the team aims to identify the most effective vaccine strategies and improve the overall health of affected women. The clinical trial is recruiting participants, and interested women are encouraged to contact the research team for more information. To learn more about this study, visit https://alsaresearch.com/current-studies/bridgeport-ct/cytomegalovirus-cmv-study/ or call 203-374-9816.
About New England Research Associates
NERA is a leading research institution with two dedicated clinical research facilities in Bridgeport, CT. Our team of experienced researchers and healthcare professionals is dedicated to conducting innovative research studies that can help advance the field of medicine and improve patients' lives.
Jeff Stein, New England Research Associates, https://alsaresearch.com/current-studies/bridgeport-ct/cytomegalovirus-cmv-study/, 1 (203) 374-9816, [email protected]
Share this article